WO2023092479A1 - 人类蜕膜间充质干细胞的细胞培养上清液的用途 - Google Patents

人类蜕膜间充质干细胞的细胞培养上清液的用途 Download PDF

Info

Publication number
WO2023092479A1
WO2023092479A1 PCT/CN2021/133606 CN2021133606W WO2023092479A1 WO 2023092479 A1 WO2023092479 A1 WO 2023092479A1 CN 2021133606 W CN2021133606 W CN 2021133606W WO 2023092479 A1 WO2023092479 A1 WO 2023092479A1
Authority
WO
WIPO (PCT)
Prior art keywords
stem cell
cell culture
supernatant
mesenchymal stem
serum
Prior art date
Application number
PCT/CN2021/133606
Other languages
English (en)
French (fr)
Inventor
朱莉莉
Original Assignee
金湧长生医学生物科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 金湧长生医学生物科技股份有限公司 filed Critical 金湧长生医学生物科技股份有限公司
Priority to PCT/CN2021/133606 priority Critical patent/WO2023092479A1/zh
Priority to US17/579,595 priority patent/US20230165900A1/en
Publication of WO2023092479A1 publication Critical patent/WO2023092479A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/92—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]

Definitions

  • the invention discloses an application of a cell culture supernatant of human decidual mesenchymal stem cells.
  • DM Diabetes Mellitus
  • DFU Diabetic Foot Ulcer
  • MSCs Mesenchymal stem cells
  • the inner walls of blood vessels in healthy people are smooth. If they are damaged by non-specific damage, such as high blood pressure, hydrocarbons from cigarettes, cholesterol, high blood sugar, inflammation, trauma, etc., fatty plaques will accumulate on the injured In this way, the vascular endothelial cells are damaged, and the lipid penetrates into the middle layer of the vascular endothelium. After the lipid is peroxidized, it will induce macrophages to produce an immune response, prompt a series of cytokine secretion, and make the smooth muscle in the middle layer of the blood vessel wall hyperplasia improperly. 2.
  • peripheral arterial occlusive disease The tissue below the blocked site will suffer from pathological changes such as ischemia or gangrene due to the inability to receive sufficient nutrients and oxygen. These are collectively referred to as peripheral arterial occlusive disease.
  • a pharmaceutical composition for preventing or treating ischemic diseases comprising: an effective amount of supernatant of human decidual mesenchymal stem cells; and pharmaceutically acceptable carriers or excipients.
  • the supernatant of human decidual mesenchymal stem cells is determined by the following steps: providing a serum-free stem cell culture medium for subculture of stem cells, wherein the culture medium contains: stem cell culture medium; 0.9% to 1.1% insulin-transferrin- Selenium; and 9ng/ml to 11ng/ml epidermal growth factor; cultured in this serum-free stem cell medium for 4 to 12 days; collected and added with 40mg/ml to 80mg/ml trehalose and 10mg/ml to 30mg/ml dextran to the cultured serum-free stem cell culture fluid; and filtering the serum-free stem cell culture fluid.
  • An effective amount of the supernatant of human decidual mesenchymal stem cells can be defined by the weight of the supernatant liquid freeze-dried powder.
  • the supernatant liquid freeze-dried powder is added in an amount of 0.1879 grams, 0.22 grams, 0.247 grams. gram weight.
  • the supernatant of an effective amount of human decidual mesenchymal stem cells can be defined by the number of extracellular vesicles.
  • the total amount of extracellular vesicles in the supernatant of human decidual mesenchymal stem cells is 1 ⁇ 10 6 to 1 ⁇ 10 11 particles per ml.
  • the total number of extracellular vesicles in the supernatant of human decidual mesenchymal stem cells is 1 ⁇ 10 7 to 1 ⁇ 10 10 particles per milliliter.
  • the ischemic disease is diabetic foot ulcer.
  • pharmaceutically acceptable carrier or “excipient” or “pharmaceutically acceptable carrier or excipient” or “bioavailable (bioavailable) carrier” or “bioavailable carrier or excipient” This includes, but is not limited to, solvents for preservation, dispersants, coatings, antimicrobials, antifungals or absorption delaying agents for formulation and any other known compound. Generally, these carriers or excipients have no disease-treating activity by themselves.
  • the pharmaceutical composition or formulation prepared by using the novel compound disclosed in the present invention or its derivative in combination with a pharmaceutically acceptable carrier or excipient will not cause side effects, allergies or other inappropriate reactions in animals or humans.
  • compositions or formulations comprising the novel compounds of the present invention or derivatives thereof may be administered intravenously, orally, by inhalation or topically by nasal, rectal, vaginal or sublingual administration for therapeutic effect.
  • the present invention provides a use of a medicament for preventing or treating ischemic diseases.
  • Fig. 1 is a Doppler blood flow imager analysis diagram of a mouse lower limb ischemia model.
  • Fig. 2 is an analysis diagram of the number of extracellular vesicles in the cell culture supernatant of human decidual mesenchymal stem cells.
  • Fig. 3 is a graph showing the treatment of the lower limb ischemia model of diabetic mice with the supernatant of human decidual mesenchymal stem cells.
  • the solution contains MCDB201 formula medium, insulin-transferrin-selenium (insulin transferrin selenium, ITS) with a concentration between 0.9% and 1.1%, and epidermal growth factor (epidermal growth factor) with a concentration between 9ng/ml and 11ng/ml , EGF), cultured for 4 to 12 days.
  • insulin-transferrin-selenium insulin transferrin selenium, ITS
  • epidermal growth factor epidermal growth factor
  • EGF epidermal growth factor
  • the added substances of this cell culture solution formula need to be selected from non-animal sources, which is a chemically defined medium composed of no serum, no animal sources and no phenol red, so there is no need to consider the effects of animals or serum substances on the human body. Infection or allergic reaction is triggered, and the supernatant can be collected directly when the cells reach the best state for subsequent application of the present invention.
  • non-animal sources which is a chemically defined medium composed of no serum, no animal sources and no phenol red
  • trehalose and 20 mg/ml dextran were added to the supernatant, mixed evenly, and then filtered with a filter membrane with a pore size below 0.22 ⁇ M. Fill a cryogenic container with 2 ml of the filtered supernatant.
  • the freeze dryer needs to be pre-cooled to -30°C (one to two hours), put the prepared sample into the vacuum box, and after the box cools down to -50°C for two to three minutes (rapidly freezes to a solid state), start the negative Pump the box to 200 torr, and maintain this negative pressure for 60 hours, so that the ice sublimates into water vapor, thereby removing the moisture in the dried object. After completion, raise the temperature of the box to 10°C, collect the lyophilized powder sample, seal it, and store it at -20°C to -80°C.
  • the total number of extracellular vesicles in the supernatant of human decidual mesenchymal stem cells is 9.7x10 7 , 8.6x10 8 , 1.1x10 9 , 1.5x10 9 , 2.3x10 9 , 1.45 ⁇ 10 9 .
  • mice were anesthetized with 2.5% isoflurane gas to perform femoral artery ligation, and 0.75%, 100 ⁇ L bupivacaine was injected intraperitoneally for three days after the operation to relieve pain, and Doppler A blood flow imager was used to analyze and record the blood flow data of the mouse lower limbs.
  • the supernatant freeze-dried powder is redissolved in 400 ⁇ L PBS, and the cell culture supernatant of the redissolved human decidual mesenchymal stem cells is injected intramuscularly or intraperitoneally. .
  • the streptozotocin diabetic mouse model is to inject 40mg/kg streptozotocin into the abdominal cavity continuously for 5 days starting from the first day of the experiment, and the mice are fasted on the 14th day of the experiment and tested by Roche (Diastix) Urine sugar value, when the urine sugar value is higher than 3 for two consecutive days, measure the blood sugar after 6 hours of fasting, and the induction is successful when the test result is greater than 300mg/dl.
  • mice were anesthetized with 2.5% isoflurane gas to perform femoral artery ligation, and 0.75%, 100 ⁇ L bupivacaine was injected intraperitoneally for three days after the operation to relieve pain, and Doppler blood flow imaging was performed Analyze and record blood flow data of mouse lower limbs.
  • the supernatant freeze-dried powder was redissolved in 400 ⁇ L PBS, and 60 ⁇ L was injected into the inner and outer muscles of the calf and thigh respectively by intramuscular injection, a total of 180 ⁇ L supernatant Reconstituted solution;
  • 180 ⁇ L of the supernatant reconstituted solution was injected into the abdominal cavity of the experimental animal once after the operation for the test.
  • Doppler flow imaging was used to collect and quantify image data for 14 consecutive days after the operation. The results showed that blood flow data higher than that of the control group could be observed in the supernatant injected intramuscularly or intraperitoneally.
  • DM diabetic mice
  • IM intramuscular injection
  • IP intraperitoneal injection
  • EX supernatant.

Abstract

一种人类蜕膜间充质干细胞培养上清液及其在制备治疗或预防缺血性疾病的药物中的用途，缺血性疾病为糖尿病足溃疡。人类蜕膜间充质干细胞培养上清液采用无血清干细胞培养液对干细胞进行继代培养，无血清干细胞培养液包含干细胞培养基、0.9％至1.1％胰岛素-转铁蛋白-硒、9ng/ml至11ng/ml表皮生长因子，培养4至12天后收集得到的无血清干细胞培养液中添加40mg/ml至80mg/ml海藻糖及10mg/ml至30mg/ml右旋糖酐。人类蜕膜间充质干细胞上清液中产生的胞外囊泡数量为每毫升1×10 6至1×10 11颗粒。

Description

人类蜕膜间充质干细胞的细胞培养上清液的用途 技术领域
本发明公开一种人类蜕膜间充质干细胞的细胞培养上清液的用途。
背景技术
糖尿病(Diabetes Mellitus,DM)是全球十大死亡原因之一。根据中国台湾卫生福利部国民健康署的统计，台湾约有200万名DM患者，2016年有9,960名患者死于DM，相比去年增加了4.5％。
根据统计，15-25％的糖尿病患者在其一生中患有糖尿病足溃疡(Diabetic Foot Ulcer,DFU)，DFU被认为是发病过程中最主要的问题，也是DM患者住院的主要原因。
迄今为止，由于糖尿病导致正常的血管新生能力受损，大量DM患者需要截肢，造成严重的并发症。
间充质干细胞(Mesenchymal stromal cells,MSCs)已被广泛研究为再生医学的理想细胞来源，能通过旁分泌作用(paracrine effect)促进血管新生。另外也有证据指出，MSC移植可以加速伤口闭合，改善临床症状，避免截肢。
健康人的血管内壁是光滑的，如果受到非特异性的伤害，如高血压、香烟的碳氢化合物、胆固醇、高血糖、发炎、受创等多项因素的伤害，会导致脂肪斑块堆积在受伤处，进而造成血管内皮细胞受损，使得脂质渗透到血管内皮中层，在脂质被过氧化后，会诱发巨噬细胞产生免疫反应、促使一连串细胞激素分泌，使得血管壁中层的平滑肌不当增生、脂肪斑块持续增厚，长久下来，血管中层会出现溃疡、出血或钙化，最后形成纤维斑块，使血管表面凹凸不平，进而与血小板作用形成血栓，导致血管阻塞。
阻塞部位以下的组织会因无法得到充足的养分与氧气，出现缺血或坏疽等病理变化，这些统称为周边动脉阻塞疾病。
其中，糖尿病患者如果长期血糖控制不佳，会加速动脉硬化及血管壁基底层增厚，造成组织血氧通透性变差、血液凝聚功能增强，易于血栓形成，进而引起管腔狭窄、阻塞，造成下肢缺血。
发明内容
本说明书中的术语“一”或“一种”是用来描述本发明的组分及成分，此术语仅为了描述方便和给予本发明的基本观念，进一步地，此描述应被理解为包括一种或至少一种，且除非明显地另有所指，表示单数时也包括复数。在申请专利范围中和“包含”一词一起使 用时，该术语“一”可表示一个或超过一个。
一种用于预防或治疗缺血性疾病的医药组合物，其包含：有效量的人类蜕膜间充质干细胞的上清液；及医药上可接受的载体或赋形剂。
人类蜕膜间充质干细胞上清液由以下步骤所决定：提供无血清干细胞培养液进行干细胞的继代培养，其中该培养液包含：干细胞培养基；0.9％至1.1％胰岛素-转铁蛋白-硒；以及9ng/ml至11ng/ml表皮生长因子；在该无血清干细胞培养液进行4至12天的培养；收集并添加40mg/ml至80mg/ml海藻糖及10mg/ml至30mg/ml右旋糖酐至经培养的无血清干细胞培养液；以及过滤该无血清干细胞培养液。
有效量的人类蜕膜间充质干细胞的上清液可由上清液体冷冻干燥粉末重量界定，在本发明的实施例中，上清液体冷冻干燥粉末添加量为0.1879克重、0.22克重、0.247克重。
有效量的人类蜕膜间充质干细胞的上清液可由胞外囊泡的数量界定，在本发明的实施例中，人类蜕膜间充质干细胞的上清液胞外囊泡数量总量为每毫升1×10 6至1×10 11颗粒。
在另一本发明的实施例中，人类蜕膜间充质干细胞的上清液胞外囊泡数量总量为每毫升1×10 7至1×10 10颗粒。
在本发明的一个实施例中，该缺血性疾病为糖尿病足溃疡。
“医药上可接受的载体”或“赋形剂”或“医药上可接受的载体或赋形剂”或“生物可利用的(bioavailable)载体”或“生物可利用的载体或赋形剂”包括但不限于为了保存的溶剂、分散剂、涂料、抗微生物剂、抗真菌剂或为了制备配方的延迟吸收剂及任何其他已知的化合物。一般而言，这些载体或赋形剂本身不具有治疗疾病的活性。通过使用本发明中公开的新颖化合物或其衍生物，结合医药上可接受的载体或赋形剂而制备的医药组合物或配方不会引起动物或人类的副作用、过敏或其他不适当的反应。因此，本发明中公开的新颖化合物或其衍生物与医药上可接受的载体或赋形剂的组合可应用于人类临床。包含本发明的新颖化合物或其衍生物的医药组合物或配方可通过静脉注射、口服、吸入或通过鼻、直肠、阴道或舌下的局部施用来达到治疗效果。
另一方面，本发明提供一种用于预防或治疗缺血性疾病的药物的用途。
附图说明
图1为小鼠下肢缺血模型的多普勒血流成像仪分析图。
图2为人类蜕膜间充质干细胞的细胞培养上清液的胞外囊泡数量分析图。
图3为糖尿病小鼠下肢缺血模型接受人类蜕膜间充质干细胞上清液治疗图。
具体实施方式
人类蜕膜间充质干细胞的细胞培养
在无尘环境空间内实施本发明步骤，以无菌操作细胞增殖培养方式，使用未混合任何血清的干细胞培养溶液进行细胞的继代培养，培养期间每三日更换新鲜的干细胞培养溶液，其中该溶液包含有MCDB201配方培养基、浓度介于0.9％至1.1％的胰岛素-转铁蛋白-硒(insulin transferrin selenium,ITS)及浓度介于9ng/ml至11ng/ml的表皮生长因子(epidermal growth factor,EGF)，进行4至12天的培养。
其中本细胞培养溶液配方各项添加物质需选择非动物来源，为无血清、非动物来源且无酚红组成的限定化学成分培养基(chemical defined medium)，因此无需考虑动物或血清物质对人体产生感染或引发过敏反应，并可以直接在细胞达到最佳状态时直接收取上清液进行本发明后续应用。
在干细胞培养以1×10 4/cm 2接种的T175Flask中，细胞密度达90％以上，即可收取总蛋白质浓度达200～300μg/ml的上清液，并执行冷冻干燥程序。
冷冻干燥制备
为保持上清液中活性因子的稳定性，向其中加入海藻糖(Trehalose)60mg/ml及右旋糖酐(Dextran)20mg/ml，混合均匀后以孔径0.22μM以下的滤膜过滤。在可耐低温容器中充填2ml过滤完成的上清液。
冷冻干燥机需先预冷至-30℃(需一至二小时)，将制备完成的样本放入真空箱中，箱体降温至-50℃二至三分钟后(急速冻结为固态)，启动负压将箱体内抽至200托，并维持此负压60小时，使冰升华为水蒸气，从而除去被干燥物中的水分。完成后，将箱体温度升至10℃，收取冻干粉样本封罐，置于-20℃至-80℃保存。
人类蜕膜间充质干细胞的细胞培养上清液的胞外囊泡数量
在本发明的实施例中，人类蜕膜间充质干细胞的上清液的胞外囊泡数量的总量为9.7x10 7、8.6x10 8、1.1x10 9、1.5x10 9、2.3x10 9、1.45×10 9。
链脲佐菌素糖尿病小鼠模型
以2.5％的异氟醚(isoflurane)气体麻醉C57BL/6J小鼠以进行股动脉结扎手术，术后给予0.75％、100μL的布比卡因(bupivacaine)腹腔注射三天缓解疼痛，进行多普勒血流成像仪分析记录小鼠下肢血流数据。小鼠在完成股动脉结扎手术后尚未缝合皮肤时，将上清液冷冻干燥粉以400μL PBS回溶，通过肌肉注射或腹腔注射该回溶的人类蜕膜间充质干细胞的细胞培养上清液。
链脲佐菌素糖尿病小鼠模型是将40mg/kg的链脲佐菌素，在实验的第1天开始连续腹腔注射5天，在实验的第14天使小鼠空腹并通过罗氏(Diastix)检测尿糖值，当该尿糖值连续两天高于3后，测量禁食6小时后的血糖，当测试结果大于300mg/dl即诱导成功。
多普勒血流成像仪分析
以2.5％的异氟醚(isoflurane)气体麻醉小鼠以进行股动脉结扎手术，术后给予0.75％、100μL的布比卡因(bupivacaine)腹腔注射三天缓解疼痛，进行多普勒血流成像仪分析记录小鼠下肢血流数据。
小鼠在完成股动脉结扎手术后尚未缝合皮肤时，将上清液冷冻干燥粉以400μL PBS回溶、通过肌肉注射分别在小腿及大腿的内、外侧肌肉上各注射60μL，共180μL上清液回溶液体；腹腔注射组则于手术后一次注射180μL上清液回溶液体至实验动物腹腔，进行试验。
根据图1的影像结果图，发现小鼠手术后其右足血流减少，但在接受治疗后于第7天、第14天均可观察到治疗组右足血流比对照组恢复程度高。
根据图2的人类蜕膜间充质干细胞的细胞培养上清液的胞外囊泡数量分析结果图，上清液通过纳米颗粒追踪分析(Nanoparticle Tracking Analysis,NTA)，分析显示上清液中含有7.25×10 8/ml胞外囊泡(extracellular vesicles)，由于冻干粉由2ml上清液干燥而成，故每份上清液含有1.45×10 9胞外囊泡。
根据图3的糖尿病小鼠下肢缺血模型接受人类蜕膜间充质干细胞的上清液治疗结果图，以链脲佐菌素诱导C57BL/6J小鼠的糖尿病症状，然后进行下肢缺血手术并给予肌肉注射和腹腔注射处理。
手术后连续14天使用多普勒血流成像仪收集影像数据并量化，结果显示肌肉注射或腹腔注射上清液都可观察到比对照组高的血流数据。
整体而言，糖尿病小鼠相比健康小鼠其血流自然恢复能力较差，在此状态下，施用人类蜕膜间充质干细胞上清液则可有效改善血流供应的效果。数据表示平均值±标准偏差。DM：糖尿病小鼠；IM：肌肉注射；IP：腹腔注射；EX：上清液。

Claims (8)

  1. 一种人类蜕膜间充质干细胞上清液，其中所述人类蜕膜间充质干细胞上清液由以下步骤决定：
    (a)提供无血清干细胞培养液进行干细胞的继代培养，其中所述无血清干细胞培养液包含:干细胞培养基；
    0.9％至1.1％胰岛素-转铁蛋白-硒；以及
    9ng/ml至11ng/ml表皮生长因子；
    (b)用所述无血清干细胞培养液进行4至12天的培养；
    (c)收集并添加40mg/ml至80mg/ml海藻糖及10mg/ml至30mg/ml右旋糖酐至经培养的无血清干细胞培养液；以及
    (d)过滤所述经培养的无血清干细胞培养液。
  2. 如权利要求1所述的人类蜕膜间充质干细胞上清液，其中产生的胞外囊泡数量为每毫升1×10 6至1×10 11颗粒。
  3. 如权利要求2所述的人类蜕膜间充质干细胞上清液，其中所述产生的胞外囊泡数量为每毫升1×10 7至1×10 10颗粒。
  4. 如权利要求1所述的人类蜕膜间充质干细胞上清液，其中所述无血清干细胞培养液为MCDB201配方培养基。
  5. 如权利要求1所述的人类蜕膜间充质干细胞上清液，其中所述人类蜕膜间充质干细胞上清液以冷冻干燥法保存。
  6. 一种医药组合物用于制备治疗或预防缺血性疾病的药物的用途，其中所述医药组合物如权利要求1所述的步骤决定，其进一步包含医药上可接受的载体、稀释剂或赋形剂。
  7. 如权利要求6所述的用途，其中所述缺血性疾病为糖尿病足溃疡。
  8. 如权利要求6所述的用途，其中给药途径为肌肉注射或腹腔注射。
PCT/CN2021/133606 2021-11-26 2021-11-26 人类蜕膜间充质干细胞的细胞培养上清液的用途 WO2023092479A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2021/133606 WO2023092479A1 (zh) 2021-11-26 2021-11-26 人类蜕膜间充质干细胞的细胞培养上清液的用途
US17/579,595 US20230165900A1 (en) 2021-11-26 2022-01-20 Use of human decidual mesenchymal stem cell culturing supernatants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2021/133606 WO2023092479A1 (zh) 2021-11-26 2021-11-26 人类蜕膜间充质干细胞的细胞培养上清液的用途

Publications (1)

Publication Number Publication Date
WO2023092479A1 true WO2023092479A1 (zh) 2023-06-01

Family

ID=86501150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/133606 WO2023092479A1 (zh) 2021-11-26 2021-11-26 人类蜕膜间充质干细胞的细胞培养上清液的用途

Country Status (2)

Country Link
US (1) US20230165900A1 (zh)
WO (1) WO2023092479A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107022521A (zh) * 2017-02-13 2017-08-08 广东唯泰生物科技有限公司 壁蜕膜组织冻存、复苏及分离培养间充质干细胞的方法
CN108456656A (zh) * 2018-03-26 2018-08-28 北京贝诗丹生物科技有限公司 DBMSCs活性物质、制备方法及其在护肤品中的应用
CN109097391A (zh) * 2018-07-11 2018-12-28 个体化细胞治疗技术国家地方联合工程实验室（深圳） 一种大规模生产蜕膜间充质干细胞活性因子的方法及其应用
CN111821317A (zh) * 2020-08-14 2020-10-27 江苏中衍生科细胞技术研究院有限公司 一种人胎盘蜕膜间干细胞分泌因子冻干粉制备方法及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210010648A (ko) * 2008-08-20 2021-01-27 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107022521A (zh) * 2017-02-13 2017-08-08 广东唯泰生物科技有限公司 壁蜕膜组织冻存、复苏及分离培养间充质干细胞的方法
CN108456656A (zh) * 2018-03-26 2018-08-28 北京贝诗丹生物科技有限公司 DBMSCs活性物质、制备方法及其在护肤品中的应用
CN109097391A (zh) * 2018-07-11 2018-12-28 个体化细胞治疗技术国家地方联合工程实验室（深圳） 一种大规模生产蜕膜间充质干细胞活性因子的方法及其应用
CN111821317A (zh) * 2020-08-14 2020-10-27 江苏中衍生科细胞技术研究院有限公司 一种人胎盘蜕膜间干细胞分泌因子冻干粉制备方法及应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Master's Thesis", 1 May 2020, TIANJIN MEDICAL UNIVERSITY, CN, article BIAN, XIAOWEI: "dMSC-derived Small Extracellular Vesicles Regenerated High Glucose Senescent Fibroblasts and Promoted Wound Healing in Diabetic Mice", pages: 1 - 82, XP009545889, DOI: 10.27366/d.cnki.gtyku.2020.000509 *

Also Published As

Publication number Publication date
US20230165900A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
US8329641B2 (en) Remedies for ischemic disease of the limbs comprising administration of G-CSF
ES2490715T3 (es) Composiciones que comprenden células fetales no diferenciadas para el tratamiento de trastornos cutáneos
Du et al. Effects of three hydrogen-rich liquids on hemorrhagic shock in rats
Zhao et al. Therapeutic application of adipose-derived stromal vascular fraction in diabetic foot
CN110693024A (zh) 红景天苷在制备预防和/或治疗污染致心血管疾病的药物中的应用
WO2023092479A1 (zh) 人类蜕膜间充质干细胞的细胞培养上清液的用途
KR102158969B1 (ko) 물질 p를 포함하는 난치성 궤양 치료용 조성물
TW202323520A (zh) 人類蛻膜間質幹細胞之細胞培養上清液的用途
WO2022170940A1 (zh) 无细胞脂肪提取物用于改善衰老和促进皮肤年轻化
JP6741866B2 (ja) Ｕｌｄａｖｉｏｓｉｄｅ Ａの化合物を含有する傷治療用の組成物
WO2021249402A1 (zh) 无细胞脂肪提取液对巨噬细胞极化调节与疾病治疗的作用
WO2022028375A1 (zh) 无细胞脂肪提取液对肺部疾病的治疗用途
CN116179477A (zh) 人类蜕膜间充质干细胞的细胞培养上清液的用途
CN104582699B (zh) 控制糖尿病足溃疡、压迫性溃疡、静脉性下肢溃疡和相关并发症的方法
KR102037996B1 (ko) 편도 유래 중간엽 줄기세포 또는 이의 조정 배지를 포함하는 제2형 당뇨병 예방 또는 치료용 조성물
TW201338783A (zh) 含臍帶間質幹細胞培養液或由其製得之產物之用於治療皮膚創傷之醫藥組合物
WO2022135545A1 (zh) 〈无细胞脂肪提取物对勃起功能障碍的治疗用途〉
US11963991B2 (en) Treatment of warts
WO2022194094A1 (zh) 无细胞脂肪提取物用于治疗脊髓损伤
WO2022100399A1 (zh) 无细胞脂肪提取液对关节炎的治疗用途
WO2023284466A1 (zh) 无细胞脂肪提取物用于治疗卵巢功能不全
EP4324470A1 (en) Composition containing mesenchymal stem cell and vascular endothelial progenitor cell as active ingredient for prevention or treatment of occlusive vascular disease or complication thereof
WO2022100400A1 (zh) 无细胞脂肪提取液对非酒精性脂肪肝炎的治疗用途
KR100352148B1 (ko) 베타-시토스테롤을 포함하는 혈관형성 촉진 및 관절염예방 및 치료용 조성물
Ji et al. Molecular Mechanism of Extractum Liquidum Drug Loading Materials on Promoting Chronic Wound Tissue Repair Through Phosphatidylinositol 3 Kinase/Protein Kinase B/Hypoxia Induction Factor 1α Signal Pathway

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21965213

Country of ref document: EP

Kind code of ref document: A1